Dr. Balar discusses the background behind phase 2 studies of pembrolizumab in bladder cancer

Arjun V. Balar, MD, describes the 2 “very distinct patient populations” of separate phase 2 studies from ASCO 2021 involving the treatment pembrolizumab (Keytruda).

In this video, Arjun V. Balar, MD, discusses the background behind the ASCO 2021 abstracts “First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study” and “Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.” Balar is an associate professor of medicine at the NYU Grossman School of Medicine and genitourinary medical oncology program director at NYU Langone’s Perlmutter Cancer Center, New York.